Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neighbourly Pharmacy Inc T.NBLY

Neighbourly Pharmacy Inc. is a Canada-based company that operates a network of community pharmacies. The Company is an owner and operator of retail pharmacies located throughout Canada under banners such as IDA/Guardian, Pharmachoice, Pharmasave and Remedy’s RX. The Company, through its subsidiaries, owns and operates a network of retail pharmacies known as Rubicon Pharmacies (Rubicon or Rubicon Pharmacies. The Company owns and operates approximately 287 locations across seven provinces and one territory, a coast-to-coast footprint that provides scale and diversification. The Company’s pharmacies provide accessible healthcare with a personal touch. The Company also owns British Columbia-based pharmacies.


TSX:NBLY - Post by User

Post by Possibleidiot01on Jan 15, 2024 7:01am
144 Views
Post# 35826464

Enhanced offer

Enhanced offerPursuant to the Arrangement Agreement, the Purchaser would acquire all of the Common Shares in the capital of Neighbourly, other than those Common Shares already owned by PCP or its affiliates, for $18.50 per Common Share in cash (representing a consideration of approximately $415 million ), plus one CVR per Common Share, which will entitle the holder thereof to an additional cash payment equal to $0.61 per CVR if the Company's Pro-Forma Adjusted EBITDA for the fiscal year ending on March 28, 2026 (" Fiscal 2026 ") is at or above $128.0 million (the " EBITDA Target ") (representing an additional potential payment of approximately $13.7 million ). If the Company's Pro-Forma Adjusted EBITDA for Fiscal 2026 is below the EBITDA Target, then no additional consideration will be payable to the holders of CVRs.

POTENTIALLY. ENHANCED. or maybe not. Trying to make the reduced offer from $20.50 palatable with a bribe IMO.

<< Previous
Bullboard Posts
Next >>